Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-06-06
1998-01-27
Ivy, C. Warren
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 31445
Patent
active
057122911
ABSTRACT:
The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis. Importantly, these compounds can be administered orally.
REFERENCES:
patent: 2830991 (1958-04-01), Keller et al.
patent: 3560495 (1971-02-01), Frankus et al.
patent: 3563986 (1971-02-01), Frankus et al.
patent: 3625946 (1971-12-01), Koch et al.
patent: 3705162 (1972-12-01), Graudums et al.
patent: 4552888 (1985-11-01), Koppel et al.
patent: 4808402 (1989-02-01), Leibovich et al.
patent: 4994443 (1991-02-01), Folkman et al.
patent: 5001116 (1991-03-01), Folkman et al.
patent: 5021404 (1991-06-01), Folkman et al.
patent: 5134127 (1992-07-01), Stella et al.
patent: 5260329 (1993-11-01), Mongelli et al.
patent: 5635517 (1997-06-01), Muller et al.
Phillips, G.D. et al, "Tumor Necrosis Factor-alpha (rh TNF) Fails to Stimulate Angiogenesis in the Rabbit Cornea" Anatomical Record, 1996 (May), 245(1), pp. 53-56, abstract only.
Montrucchio, G. et al, "Tumor Necrosis Factor-alpha Induced Angiogenesis depends on in situ Platelet-Activating Gactor Biosynthesis" J. Exp. Med. 1994(Jul. 1), 180(1), pp. 377-382, abstract only.
Hu, D.E. et al, "Inhibition of Angiogenesis in Rats by IL-1 Receptor Antagonist and Selected Cytokine Antibodies" Inflammation, 1994(Feb.), 18(1), pp. 45-58, abstract only.
Fajardo, L.F. et el, "Dual Role of Tumor Necrosis Factor-alpha in Angiogenesis" Am. J. Pathol. 1992(May), 140(3), PP. 539-544, abstract only.
Fabro, S. et al., "Teratogenic Activity of Thalidomide and Related Compounds," Life Sciences, 3:987-992 (1964).
Shealy et al., "D-and L-Thalidomide," Chem. and Indus., pp. 1030-1031 (Jun. 12, 1965).
Folkman, "Tumor Angiogenesis: Therapeutic Implications," The New England Journal of Medicine, 285(21):1182-1186 (Nov. 18, 1971).
Jonsson, N. Ake, et al., "Chemical Structure and Teratogenic Properties," Acta Pharm. Succica, 9:521-542, 431-446, 543-562 (1972).
Eriksson, Sven O., "Synthesis and Alkaline Hydrolysis of some N-substituted Phthalimides," Acta Pharm. Sucecica, 10:63-74 (1973).
Gimbrone et al., "Tumor Growth and Neovascularization: An Experimental Model Using the Rabbit Cornea," J. Nat'l Cancer Institute, 52(2):413-419 (1974).
Fickentscher, K., "Stereochemical Properties and Teratogenic Activity of Some Tetrahydrophthalimides," Mol. Pharmacology, 13:133-141 (1977).
Knighton et el., "Avascular And Vascular Phases Of Tumor Growth In The Chick Embryo," Br. J. Cancer, 35:347-356 (1977).
Blaschke, "Chromatographic Separation of Racemie Thalidomide and Teratogenic Activity of its Enantiomers (Chromatographische Racemattrennung von Thalidomid und teratogene Wirkung der Enantiomere)," Drug Research, 29 (II/10): 1640-1642 (1979). (English lang. summary on first page).
Muthukkaruppan et al., "Angiogenesis in the Mouse Cornea," Science, 205:1416-1418 (Sep. 28, 1979).
Waters, et al., "Treatment of Ulcerative Colitis with Thalidomide," British Medical Journal, p. 792 (Mar. 24, 1979).
Flohe et al., "Studies on the Hypothetical Relationship of Thalidomide-induced Embryopathy and Collagen Biosynthesis," Arzneimittelforschung (Germany, West), 31(2):315-20 (1981).
Helm, Drug Research, 31(I/6): 941-949 (1981).
Taylor et al., Nature, 297: p. 307 (1982).
Belaube et al., "Should Thalidomide be Rehabilitated?, " Sem. Hop. Paris, 59(45):3101-3104 (Dec. 8, 1983).
Folkman et al., Science, 221: p. 719 (1983).
Hendler, Sheldon S. et al., "Thalidomide for Autoimmune Disease," Medical Hypotheses, 10:437-443 (1983).
Crum et al., Science, 230: 1375 et seq. (1985).
Koch, H.P. et al., "Thalidomide and Cogeners as Anti-inflammatory Agents," Progress in Medicinal Chemistry, 22:166-242 (1985).
Sidky et al., Cancer Research, 47: pp. 5155-5161 (1987).
Srivastava et al., "The Prognostic Significance of Tumor Vascularity in Internediate-Thickness Skin Melanoma," Am. J. Pathol., 133:419-423 (1988). (abstract from MEDLINE:Accession No. 06745734).
Chen et al., "Plasma Pharmacokinetics and Urinary Excretion of Thalidomide After Oral Dosing in Healthy Male Volunteers," Drug Metabolism and Disposition, 17(4):402-405 (1989).
White et al., New England J. Med., 320: pp. 1197-1200 (1989).
Folkman et al., "Induction of Angiogenesis During the Transition from Hyperplasia to Neoplasia," Nature, 339:58-61 (May 4, 1989).
"Thalidomide," The Merck Index, Eleventh Edition, Budavari et al., eds., Merck & co., New Jersey, p. 9182 (1989).
Eger, K. et al., "Synthesis, Central Nervous System Activity and Teratogenicity of a Homothalidomide," Arneim.-Forsch/Drug Res.40 (II. Nr. 10):1073-1075 (1990).
Ingber et al., "Synthetic Analogs Of Fumagillin That Inhibit Angiogenesis And Supress Tomour Growth," Nature, 348:555-557 (Dec. 6, 1990).
Brem et al., Neurosurg., 74: 441-446 (1991).
Matsuyama, Toshifumi, "Cytokines and HIV infection: is AIDS a Tumor Necrosis Factor Disease?," AIDS, 5(12):1405-1417 (1991).
Weidner et al., "Tumor Angiogenesis and Metastasis--Correlation in Invasive Breast Carcinoma," N.E.J. Med., 324(1):1-8(1991).
Colville-Nash et al., "Angiogenesis and Rheumaoid Arthritis: Pathogenic and Therapeutic Implications," Ann. Rheum. Dis., 51:919-925 (1992).
Folkman and Shing, "Angiogenesis," J. Biol. Chem., 267(16):10931-10934 (1992).
Schweigerer and Fotsis, "Angiogenesis and angiogenesis inhibiiors in paediatric diseases," Eur. J. Pediatr. 151:472-476 (1992).
Torry and Rongish, "Angiogenesis in the Uterus: Potential Regulation and Relation to Tumor Angiogenesis," Am. J. Reprod. Immunol., 27:171-179 (1992).
Vogelsang et al., "Thalidomide for the Treatment of Chronic Graft-Versus-Host Disease," New England Journal of Medicine, 326:1055-1058 (1992).
Weidner et al., "Angiogenesis in Prostate Carcinoma," Am. J. Path., 143(2):401-409 (1993).
D'Amato et al., "Thalidomide is an Inhibitor of Angiogenesis," PNAS USA, 91:4082-4085 (1994).
Oikawa et al., "Eponemycin, A Novel Antibiotic, is a Highly Powerful Angiogenesis Inhibitor," Biochem. Biophys. Res. Comm., 181(3):1070-1076 (Dec. 31, 1991).
Otsuka et al., "A New Potent Angiogenesis Inhibitor, FR-118487," J. Microb. Biotech., 1(3):163-168 (1991).
De, A.U. et al, J. Pharm. Sci. 1975, 64(2), pp. 262-266.
Gutierrez-Rodriguez, O. et al, J. Rheumatol. 1989, 16(2), pp. 158-163.
Hatfill, S.J. et al, Leuk. Res. 1991, 15(2-3), pp. 129-136.
Goihman-Yahr, M. et al, Int. Arch. Allergy Appl. Immunol. 1978, 57(4), pp. 317-332.
Mummery, C.L. et al, Toxicol. Lett. 1983, 18(3), pp. 201-209.
Dahlen Garth M.
Ivy C. Warren
The Children's Medical Center Corporation
LandOfFree
Methods and compositions for inhibition of angiogenesis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for inhibition of angiogenesis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for inhibition of angiogenesis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-342687